Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.
AI summary
In a monitoring inquiry, BBB National Programs’ National Advertising Division recommended that Nucleus Genomics, Inc. modify or discontinue certain express and implied advertising claims for its Nucleus IVF+ service, including claims that Nucleus IVF+ could accurately compare embryos' disease risks, identify which embryo would grow up tallest or smartest, and determine a future child’s eye and hair colors. Nucleus will appeal the National Advertising Division’s (NAD) decision In a monitoring inquiry, BBB National Programs’ National Advertising Division recommended that Nucleus Genomics, Inc. modify or discontinue certain express and implied advertising claims for its Nucleus IVF+ service, including claims that Nucleus IVF+ could accurately compare embryos' disease risks, identify which embryo would grow up tallest or smartest, and determine a future child’s eye and hair colors. Nucleus will appeal the National Advertising Division’s (NAD) decision
AI commentary is generated from public news feeds and is not investment advice.